Voyager Therapeutics (NASDAQ:VYGR) Insider Todd Alfred Carter Sells 3,525 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Todd Alfred Carter sold 3,525 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $3.85, for a total value of $13,571.25. Following the completion of the transaction, the insider owned 153,193 shares of the company’s stock, valued at approximately $589,793.05. This trade represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $3.65 on Thursday. The company has a market cap of $202.94 million, a price-to-earnings ratio of -1.69 and a beta of 1.30. The stock’s 50-day moving average is $4.02 and its two-hundred day moving average is $4.09. Voyager Therapeutics, Inc. has a 1-year low of $2.64 and a 1-year high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.06. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%.The business had revenue of $11.15 million during the quarter, compared to analysts’ expectations of $7.86 million. Equities research analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Wedbush restated an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright dropped their price objective on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Voyager Therapeutics by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock valued at $15,178,000 after purchasing an additional 40,147 shares during the last quarter. Erste Asset Management GmbH increased its position in Voyager Therapeutics by 7.0% during the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock worth $4,718,000 after buying an additional 78,348 shares during the period. Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 1.1% in the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after buying an additional 11,929 shares during the last quarter. AQR Capital Management LLC lifted its stake in Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after buying an additional 317,927 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of Voyager Therapeutics by 3.9% in the third quarter. UBS Group AG now owns 473,100 shares of the company’s stock valued at $2,209,000 after acquiring an additional 17,558 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.